PFBT
PTGX icon

Parkside Financial Bank & Trust’s Protagonist Therapeutics PTGX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.32K Hold
76
– – ﹤0.01% 1681
2026
Q1 		$8.01K Sell
76
-8
-10% -$708 ﹤0.01% 1660
2025
Q4 		$7.34K Buy
84
+39
+87% +$3.19K ﹤0.01% 1683
2025
Q3 		$2.99K Hold
45
– – ﹤0.01% 1884
2025
Q2 		$2.49K Buy
45
+11
+32% +$528 ﹤0.01% 1921
2025
Q1 		$1.65K Buy
34
+30
+750% +$1.26K ﹤0.01% 1942
2024
Q4 		$155 Hold
4
– – ﹤0.01% 2085
2024
Q3 		$180 Buy
+4
New +$162 ﹤0.01% 2024

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Parkside Financial Bank & Trust's PTGX Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 76 shares worth $9.32K. The position accounts for ﹤0.01% of the portfolio, ranked #1681.

Parkside Financial Bank & Trust first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Parkside Financial Bank & Trust held 76 shares of Protagonist Therapeutics worth $9.32K as of Q2 2026.
  • Parkside Financial Bank & Trust left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #1681 holding.
  • Parkside Financial Bank & Trust first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.